{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:24:53Z","timestamp":1790076293126,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11523-017-0529-y","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:09:40Z","timestamp":1507680580000},"page":"805-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6253-1833","authenticated-orcid":false,"given":"Amandine","family":"Gouverneur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Claraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Fourrier-R\u00e9glat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada","family":"Miremont-Salam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Noize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"529_CR1","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD. Based on November 2015 SEER data submission, posted to the SEER web site, April 2016. \nhttp:\/\/seer.cancer.gov\/csr\/1975_2013\/sections.html\n\n Accessed 15 June 2017."},{"key":"529_CR2","doi-asserted-by":"crossref","first-page":"e74599","DOI":"10.1371\/journal.pone.0074599","volume":"8","author":"M Rio Del","year":"2013","unstructured":"Del Rio M, Mollevi C, Vezzio-Vie N, et al. Specific extracellular matrix remodeling signature of colon hepatic metastases. PLoS One. 2013;8:e74599.","journal-title":"PLoS One"},{"key":"529_CR3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Cutsem Van","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386\u2013422.","journal-title":"Ann Oncol"},{"key":"529_CR4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/annonc\/mdu253","volume":"26","author":"D Papamichael","year":"2015","unstructured":"Papamichael D, Audisio R, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463\u201376.","journal-title":"Ann Oncol"},{"key":"529_CR5","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","volume":"22","author":"L Talarico","year":"2004","unstructured":"Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626\u201331.","journal-title":"J Clin Oncol"},{"key":"529_CR6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.dld.2016.05.011","volume":"48","author":"T Aparicio","year":"2016","unstructured":"Aparicio T, Pamoukdjian F, Quero L, et al. Colorectal cancer care in elderly patients: Unsolved issues. Dig Liver Dis. 2016;48:1112\u20138.","journal-title":"Dig Liver Dis"},{"key":"529_CR7","doi-asserted-by":"publisher","unstructured":"Gouverneur A, Salvo F, Berda\u00ef D, et al. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. J Geriatr Oncol. 2017; \nhttps:\/\/doi.org\/10.1016\/j.jgo.2017.08.001\n\n.","DOI":"10.1016\/j.jgo.2017.08.001"},{"key":"529_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000320222","volume":"78","author":"M Kozloff","year":"2010","unstructured":"Kozloff M, Berlin J, Flynn P, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78:329\u201339.","journal-title":"Oncology"},{"key":"529_CR9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jgo.2016.03.004","volume":"7","author":"M Rouyer","year":"2016","unstructured":"Rouyer M, Fourrier-R\u00e9glat A, Smith D, et al. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. J Geriatr Oncol. 2016;7:187\u201394.","journal-title":"J Geriatr Oncol"},{"key":"529_CR10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/bjc.2011.554","volume":"106","author":"C Jehn","year":"2012","unstructured":"Jehn C, B\u00f6ning L, Kr\u00f6ning H, et al. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012;106:274\u20138.","journal-title":"Br J Cancer"},{"key":"529_CR11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11523-013-0296-3","volume":"9","author":"A Fourrier-R\u00e9glat","year":"2014","unstructured":"Fourrier-R\u00e9glat A, Smith D, Rouyer M, et al. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort. Target Oncol. 2014;9:311\u20139.","journal-title":"Target Oncol"},{"key":"529_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11523-014-0311-3","volume":"10","author":"E Tahover","year":"2015","unstructured":"Tahover E, Hubert A, Temper M, et al. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group. Target Oncol. 2015;10:55\u201363.","journal-title":"Target Oncol"},{"key":"529_CR13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"529_CR14","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255\u20139.","journal-title":"Lancet"},{"key":"529_CR15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"529_CR16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"529_CR17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Cutsem Van","year":"2015","unstructured":"Van Cutsem E, Lenz H-J, K\u00f6hne C-H, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33:692\u2013700.","journal-title":"J Clin Oncol"},{"key":"529_CR18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2016.1186649","volume":"17","author":"JJM Kwakman","year":"2016","unstructured":"Kwakman JJM, Punt CJA. Oral drugs in the treatment of metastatic colorectal cancer. Expert Opin Pharmacother. 2016;17:1351\u201361.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"529_CR19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0305-7372(10)00036-8","volume":"36","author":"O Bouch\u00e9","year":"2010","unstructured":"Bouch\u00e9 O, Beretta GD, Alfonso PG, et al. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat Rev. 2010;36(Suppl 1):S1\u201310.","journal-title":"Cancer Treat Rev"},{"key":"529_CR20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","volume":"18","author":"H Hurwitz","year":"2013","unstructured":"Hurwitz H, Tebbutt N, Kabbinavar F, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004\u201312.","journal-title":"Oncologist"},{"key":"529_CR21","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Cutsem Van","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408\u201317.","journal-title":"N Engl J Med"},{"key":"529_CR22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/annonc\/mdq309","volume":"22","author":"T Asmis","year":"2011","unstructured":"Asmis T, Powell E, Karapetis C, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Ann Oncol. 2011;22:118\u201326.","journal-title":"Ann Oncol"},{"key":"529_CR23","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/cncr.24305","volume":"115","author":"NA Jackson","year":"2009","unstructured":"Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan\/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115:2617\u201329.","journal-title":"Cancer"},{"key":"529_CR24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/annonc\/mdr488","volume":"23","author":"TJ Price","year":"2012","unstructured":"Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012;23:1531\u20136.","journal-title":"Ann Oncol"},{"key":"529_CR25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pcad.2010.05.006","volume":"53","author":"G Curigliano","year":"2010","unstructured":"Curigliano G, Mayer EL, Burstein HJ, et al. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Prog Cardiovasc Dis. 2010;53:94\u2013104.","journal-title":"Prog Cardiovasc Dis"},{"key":"529_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-011-0204-7","volume":"6","author":"G Guetz des","year":"2011","unstructured":"des Guetz G, Uzzan B, Chouahnia K, et al. Cardiovascular toxicity of anti-angiogenic drugs. Target Oncol. 2011;6:197\u2013202.","journal-title":"Target Oncol"},{"key":"529_CR27","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.2012.48.4857","volume":"31","author":"DL Hershman","year":"2013","unstructured":"Hershman DL, Wright JD, Lim E, et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol. 2013;31:3592\u20139.","journal-title":"J Clin Oncol"},{"key":"529_CR28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5603\/CJ.2012.0084","volume":"19","author":"MF Sorrentino","year":"2012","unstructured":"Sorrentino MF, Kim J, Foderaro AE, et al. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J. 2012;19:453\u20138.","journal-title":"Cardiol J"},{"key":"529_CR29","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/annonc\/mdt019","volume":"24","author":"H Tsai","year":"2013","unstructured":"Tsai H, Marshall J, Weiss S, et al. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol. 2013;24:1574\u20139.","journal-title":"Ann Oncol"},{"key":"529_CR30","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","volume":"29","author":"HI Hurwitz","year":"2011","unstructured":"Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29:1757\u201364.","journal-title":"J Clin Oncol"},{"key":"529_CR31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1077\u201385.","journal-title":"Lancet Oncol"},{"key":"529_CR32","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040\u20138.","journal-title":"N Engl J Med"},{"key":"529_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-014-0322-0","volume":"10","author":"T Kogawa","year":"2015","unstructured":"Kogawa T, Doi A, Shimokawa M, et al. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer. Target Oncol. 2015;10:125\u201333.","journal-title":"Target Oncol"},{"key":"529_CR34","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero ALC, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol. 2007;25:5390\u20136.","journal-title":"J Clin Oncol"},{"key":"529_CR35","doi-asserted-by":"crossref","unstructured":"Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16:761\u20137.","DOI":"10.1080\/14740338.2017.1323867"},{"key":"529_CR36","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/pds.2172","volume":"20","author":"F Gonz\u00e1lez-Rubio","year":"2011","unstructured":"Gonz\u00e1lez-Rubio F, Calder\u00f3n-Larra\u00f1aga A, Poblador-Plou B, et al. Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiol Drug Saf. 2011;20:1287\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-017-0529-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0529-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0529-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T00:53:10Z","timestamp":1526431990000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-017-0529-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1007\/s11523-017-0529-y","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]}}}